Langenbeck's Archives of Surgery

, Volume 398, Issue 3, pp 431–440

Resection strategies for neuroendocrine pancreatic neoplasms

  • F. M. Watzka
  • C. Laumen
  • C. Fottner
  • M. M. Weber
  • A. Schad
  • H. Lang
  • T. J. Musholt
Original Article



Due to their rarity and lack of prospective trials, the optimal treatment of pancreatic neuroendocrine neoplasms (PNENs) is still debated. Recommendations gathered by retrospective analyses of patient data should be based on the new classification of neuroendocrine neoplasms.


In a retrospective single-center study (1990 to 2012), 127 patients with PNENs were included. Tumor stage and type of resections were analyzed to evaluate successful treatment strategies.


Seventy-nine patients (62 %) were diagnosed with stage I or II, 48 patients (38 %) with stage III or IV disease; 49.6 % of all PNENs were nonfunctional. Surgical interventions consisted of 50 enucleations, 27 distal resections, and 2 partial duodenopancreatectomies in patients with stage I or II disease. Twenty-eight patients with stage III or IV disease received a distal resection and in 13 patients, a partial duodenopancreatectomy was carried out. Exploration with debulking was performed in seven patients in stages III and IV. Stage-dependent 10-year survival rates were 93.7 (stages I and II, n = 79) and 56.0 % (stages III and IV, n = 48).


PNENs have a good prognosis if they are well-differentiated and resected completely. Organ-preserving resection does not impair the prognosis in selected cases with stage I or II. In case of hepatic metastasis and advanced tumor stage, surgical reduction can reduce symptoms and improve the survival.


Pancreatic neuroendocrine tumors Surgery Resection strategy Treatment strategies Stage Prognosis 


  1. 1.
    Akerstrom G, Hellman P (2007) Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21:87–109PubMedCrossRefGoogle Scholar
  2. 2.
    Anlauf M, Gerlach P, Schott M et al (2012) Pathology of neuroendocrine neoplasms. Chirurg (in press)Google Scholar
  3. 3.
    Bartsch DK, Fendrich V, Langer P et al (2005) Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242:757–764, discussion 764–756PubMedCrossRefGoogle Scholar
  4. 4.
    Bettini R, Mantovani W, Boninsegna L et al (2009) Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 41:49–55PubMedCrossRefGoogle Scholar
  5. 5.
    Bilimoria KY, Bentrem DJ, Merkow RP et al (2007) Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 205:558–563PubMedCrossRefGoogle Scholar
  6. 6.
    Casadei R, Ricci C, Rega D et al (2010) Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? A single-center experience. Pancreas 39:825–828PubMedCrossRefGoogle Scholar
  7. 7.
    Franko J, Feng W, Yip L et al (2010) Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg 14:541–548PubMedCrossRefGoogle Scholar
  8. 8.
    Halfdanarson TR, Rabe KG, Rubin J et al (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727–1733PubMedCrossRefGoogle Scholar
  9. 9.
    Kloppel G, Perren A, Heitz PU (2004) The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014:13–27PubMedCrossRefGoogle Scholar
  10. 10.
    Kloppel G, Rindi G, Perren A et al (2010) The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch 456:595–597PubMedCrossRefGoogle Scholar
  11. 11.
    Lawrence B, Gustafsson BI, Chan A et al (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40:1–18, viiPubMedCrossRefGoogle Scholar
  12. 12.
    Lopez Cl, Falconi M, Waldmann J et al (2012) Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. Ann Surg (in press)Google Scholar
  13. 13.
    Modlin IM, Moss SF, Gustafsson BI et al (2011) The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbecks Arch Surg 396:1145–1156PubMedCrossRefGoogle Scholar
  14. 14.
    Norton JA, Harris EJ, Chen Y et al (2011) Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg 146:724–732PubMedCrossRefGoogle Scholar
  15. 15.
    Rindi G, Falconi M, Klersy C et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104:764–777PubMedCrossRefGoogle Scholar
  16. 16.
    Solorzano CC, Lee JE, Pisters PW et al (2001) Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130:1078–1085PubMedCrossRefGoogle Scholar
  17. 17.
    Strosberg JR, Cheema A, Weber J et al (2011) Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 29:3044–3049PubMedCrossRefGoogle Scholar
  18. 18.
    Strosberg JR, Cheema A, Weber JM et al. (2012) Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg (in press)Google Scholar
  19. 19.
    Su CH, Wang SE, Kuo YJ et al (2011) Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region. Pancreas 40:253–259PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • F. M. Watzka
    • 1
  • C. Laumen
    • 1
  • C. Fottner
    • 2
  • M. M. Weber
    • 2
  • A. Schad
    • 3
  • H. Lang
    • 1
  • T. J. Musholt
    • 1
  1. 1.Endocrine Surgery, Clinic of General, Visceral- and Transplantation SurgeryUniversity Medical Center, Johannes Gutenberg University MainzMainzGermany
  2. 2.Endocrinology and Metabolic DiseasesUniversity Medical Center, Johannes Gutenberg University MainzMainzGermany
  3. 3.Institute of PathologyUniversity Medical Center, Johannes Gutenberg University MainzMainzGermany

Personalised recommendations